Serum Levels of a Prostaglandin and a Leukotriene after Thermal Mud Pack Therapy

Journal of Investigative Medicine

Volumn 46, Issue 4, 1998, Pages 140-145

  Bellometti, Simona ^a,c   Galzigna, Lauro ^b  

^a Centro Studi Termali Pd'Abano   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c Centro Studi Termali Pietro D'Abano   (Italy)

Author keywords

LTB4; Mud pack therapy; Osteoarthrosis, pain; PGE2

Indexed keywords

LEUKOTRIENE B4; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2;

AGED; ARTICLE; BLOOD; FEMALE; HEAT; HUMAN; MALE; MIDDLE AGED; OSTEOARTHRITIS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DINOPROSTONE; FEMALE; HEAT; HUMANS; LEUKOTRIENE B4; MALE; MIDDLE AGED; OSTEOARTHRITIS;

EID: 0032037136     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Dequeker J. Inverse relationship of interface between osteoporosis and osteoarthritis. J Rheumatol 1997;24:795-8.
2. Altman RD. The syndrome of osteoarthritis. J Rheumatol 1997;24:766-7
3. Lohmander SL, Felson DT. Defining the role of molecular markers to monitor disease, intervention, and cartilage breakdown in osteoarthritis. J Rheumatol 1997;24:782-5.
4. Smith MD, O'Donnell J, Highton J, Palmer DG, Rozengilds M, Roberts Thomson PJ. Immunoistochemical analysis synovial of membranes from inflammatory and noninflammatory arthritides: scarcity of CD5 positive B cells and IL-2 receptor bearing T cells. Pathology 1992;24:19-26.
5. Koch AE, Burrows JC, Haianes GK, Carlos TM, Hilan JM, Leabovieh SJ. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest 1991;64:313-20.
6. Jhonson B.A., Haianes GK, Harlow LA, Koch AE. Adhesion molecules expression in human synovial tissue. Arthritis Rheum 1993;36:137-46.
7. Farahat MN, Yanni G, Poston R, Panayi GS. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993;52:870-5.
8. Chu CQ, Feldmann M, Maini RN. Localization of tumor necrosis factor α in synovial tissue and at the cartilage pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
9. Pelletier JP, Martel-Pelletier J. Role of synovial inflammation, cytokines, and IGF-1 in the physiopathology of osteoarthritis. Rev Rhum Engl Ed 1994;61:103S-8.
10. Lohmander LS. Articular cartilage and osteoarthrosis. The role of the molecular markers to monitor breakdown, repair, and disease. J Anat 1994;184:477-92.
11. Hochberg MC, Lawrence RC, Everett DF, Cornoni-Huntley J. Epidemiologic associations of pain in osteoarthritis of the knee: data from the national Health and Nutrition Examination-I. Epidemiologic Follow-up Survey. Semin Arthritis Rheum 1989;(2 Suppl)18:4-9.
12. Altman RD, Dean DD. Introduction and overview. Pain in osteoarthritis. Semin Arthritis Rheum 1989:(2 Suppl)18:1-3.
13. Oddis CV. New perspectives in osteoarthritis. Am J Med, 1996;100(2A):10S-5.
14. 2-induced substance P release from cultured sensory neurons. Neuroscience 1996;70(2):561-5.
15. 2 on proteoglycan biosynthesis and loss in unloaded articular cartilage explants. Prostaglandins 1996;52(3):157-73.
16. 2 receptor subtype in bovine chondrocytes in culture. Br J Pharmacol 1996;118(7):1597-604.
17. Robinson DR. Lipids, mediators of inflammation. Rheum Dis Clin North Am 1987;13:385-405.
18. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human disease. N Engl J Med 1990;323:645-55.
19. Garlet JL, Snonwaert JN, Latour AM, Coffmann TM, Koeller BM. Altered inflammatory responses in leukotriene-deficient mouse. Proc Natl Acad Sci USA 1994;91:12852-6.
20. Galzigna L, Moretto C, Lalli A. Physical and biochemical changes of thermal mud after maturation. Biomed Pharmacother 1996;50:306-8.
21. Bacon P. Worldwide experience with etodolac (Lodine) 300 mg b.i.d in the treatment of osteoathrosis. Rheumatol Int 1993;13:S7-S12.
22. Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum 1994;37:1115-26.
23. Campion G. The prospects for cytokine-based therapeutic strategies in rheumatoid arthritis. Ann Rheum Dis 1994;53:485-7.
24. Bellometti S, Cecchettin M, Galzigna L. Serum antioxidant modifications in osteoarthrosic patients after mud-pack. Bioch Clin 1995;7-8:563-4.
25. Cecchettin M, Bellometti S, Lalli A, Galzigna L. Serum interleukin-1 changes in arthrosic patients after mud pack treatment. Phys Rehab Kur Med (1995);5:92-3.
26. Pelletier JP, DiBattista JA, Roughley P, McCollum R, Martel-Pelletier J. Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am 1993;19:545-68.
27. Pettiper ER, Iggs GA, Henderson B. Interleukin-1 induces leukocyte infoltration and cartilage proteoglycan degradation in the synovial joint. Proc Natl Acad Sci USA 1986;83:8749-53.
28. Robertson RP. Molecular regulation of prostaglandin synthesis. Implication for endocrine systems. Trends Endocrinol Metab 1995;6:293-7.
29. Jacobson ED, Chandury TK, Thompson WJ. Mechanisms of gastric mucosal cytoprotection by prostaglandins. Gastroenterology 1976;70:A-897
30. Vane JR, Botting RM. New insight into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-10.
31. Wittenberg RH, Willburger RE, Kleemeyer KS, Peskar BA. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 1993;36(10):1444-50.
32. 2. Spine 1996;21(3):271-7.
33. Samble EL, Wu WC. Prostaglandins in the gut and their relationship to non-steroidal anti-inflammatory drugs. Baillieres Clin Rheumatol 1989;3:247-9.
34. Robert A, Nezamis JE, Lancaster C, Hauchar AJ. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 1979;77:433-43.
35. Dvornic DM. Tissue selective inhibition of prostaglandins biosynthesis by Etodolac. J Rheumatol 1997;(47 Supp)24:40-7.
36. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
37. Griffiths RJ, Pettiper ER, Koch K, Farrel CA, Buslow R, Conklyn MJ, Smith MA, Haekman BC, Kimberly DJ, Miliei AJ. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA 1995;92:517-21.
38. Lightfoot R. Comparison of the efficacy and safety of Etodolac and piroxicam in patients with rheumatoid arthritis. J Rheumatol 1997;(47 Suppl) 24:10-16.
39. Blackburn WD. Management of osteoarthritis and rheumatoid arthritis: prospects and possibilities. Am J Med 1996; 100(2A):24S-30S.
40. Mitchell JA, Akarasereenont P, Themermann C, Flower MJ, Vane JR. Selectivity of nonsteroidal anti-inflammatory drugs inhibitors of constitutive and inducible cyclo-oxygenase. Proc Natl Acad Sci USA 1994;90:11693-7.
41. Vane JR, Botting RM. New insights into the mode of action of anti-inflammalory drugs. Inflamm Res 1995;44:1-10.
42. Peloso PM. Strategies and practice for use of nonsteroidal anti-inflammatory drugs. Scand J Rheumatol Suppl 1996;105:29-43.
43. Lee M, Gryer B, Feldmann M. Dose effects of aspirin on gastrin prostaglandins and stomach mucosal injury. Ann Intern Med 1994;120:184-9.
44. Tennenbaum H, Davis P, Russell AS, Alkinson MH, Maksymowych W, Huang SH, Bell M, Hawker GA, Juby A, Vanner S, Sibley J. An evidence based approach to prescribing NSAIDs in musculoskeletal disease: a Canadian consensus of participants. Can Med Assoc J 1996;155(1):77-88.
45. Elasthoff JD, Grosmann MI. Trends in hospital admission and death rates for peptic ulcer in the United States from 1970 to 1978. Gastroenterology 1980;78:280-5.
46. Griffin MR, Piper JM, Daugherty JR, Snowden M, Ray WA. NSAID use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
47. Nolan L, O'Malley K. Prescribing for the elderly. Part 1: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988;36:142-9.
48. Grymonpre RE, Mitenko PA, Bitar DS, Aoki FY, Montgomery PR. Drug-associated hospital admission in older medical patients. J Am Geriatr Soc 1988;36:1092-8.
49. Knight JR, Campbell AJ, Williams SM, Clark DW. Knowledgeable noncompliance with prescribed drugs in elderly subjects - a study with particular reference to nonsteroidal anti-inflammatory and antidepressant drugs. J Clin Pharm Ther 1991;16:131-7.
50. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PL, Seibert K. Selective inhibition of inducible cyclo-oxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-32.
51. Wallace J. Mechanisms of nonsteroidal anti-inflammatory drug induced gastrointestinal damage. Potential for development of gastrointestinal safe NSAlDs. Can J Physiol Pharmacol 1994;72:1493-7.
52. Lozzarin P, Cozzi F, Punzi L, Bertazzolo N, Favera R, Lalli A, Tadesco S. Serum IL-6, sIL-6R and acute phase proteins in patients with osteoarthritis undergoing mud-bath treatment in the Euganean Area. Bioch Clin 1994;19:564.
53. Vincenti E, Galzigna L, Giron GP. Serum levels of beta-endorphin during mud pack application. Acta Anaesthesiologica Italica 1985,36:5.
54. Pelletier JP, DiBattista JA, Roughley P, McCollum R, Martel-Pelletier J. Cytokines and inflammation in cartilage degradation. In: Moskowitz RW, ed. Osteoarthritis Edition of Rheumatic Disease Clinics of North America. Philadelphia W.B. Saunders 1993;545-68.
55. Bellometti S, Giannini S, Sartori L. Cytokines levels in osteoarthrosic undergoing mud bath therapy. J Invest Med 1997;45:244A.
56. Maede EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxidase synthase (cyclo-oxygenase) isoenzymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1993;268:8610-4.